Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies

  Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly
  Neutralizing HIV Antibodies

Business Wire

SEATTLE -- July 30, 2014

Theraclone Sciences, Inc., a therapeutic antibody discovery and development
company, announced today that it has entered into an agreement with Gilead
Sciences, Inc., under which Gilead received an exclusive license to develop
and commercialize products incorporating Theraclone’s broadly neutralizing
HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing
antibodies (bNAbs) were discovered in collaboration with the International
AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute using
Theraclone’s proprietary I-STAR™ technology. The I-STAR technology allows for
the rapid testing of tens of thousands of fully human antibodies to find those
with exceptional biological functions and activities.

“Through our innovative I-STAR technology, we are able to uncover unique
antibodies that have the capacity to neutralize viruses, such as HIV, that are
known to mutate and evade current therapies,” said Clifford J. Stocks, Chief
Executive Officer of Theraclone. “We look forward to collaborating with Gilead
on the development of new therapies to address HIV infection.”

Under the terms of the agreement, Theraclone received an upfront payment and
is eligible to receive additional payments based upon achievement of certain
development and commercialization milestones.

Theraclone is a biopharmaceutical company focused on the discovery and
development of novel, monoclonal antibody therapeutics for diseases that are
devastating for patients and their families and which are a significant threat
to human health. Theraclone leverages its proprietary antibody discovery
technology, I-STAR^TM (In-Situ Therapeutic Antibody Rescue), to identify rare
fully human antibodies, from immunologically relevant human subjects, that may
be developed into antibody product candidates that are potentially safer and
more effective than current therapies, or that address an unmet need. With a
primary focus on cancer and infectious disease, Theraclone has a portfolio of
innovative antibody programs at preclinical and clinical development stage
targeting serious medical conditions with a significant unmet medical need

  *Triple negative and endocrine treatment resistant HER-2 negative breast
  *Infectious disease associated cancers
  *Immune profiling of cancer patients treated with immunomodulators,
    checkpoint inhibitors or cancer vaccines
  *Gram-negative multidrug resistant bacteria
  *TCN-032 - a recombinant fully human monoclonal antibody for the treatment
    of patients hospitalized with serious influenza that has shown
    statistically significant reduction in viral load and improvement of
    clinical symptom scores in a Phase 2a viral challenge model

Theraclone is a privately held company having antibody discovery
collaborations with Pfizer, Zenyaku Kogyo and IAVI, and venture investment
from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, MPM Capital,
Amgen Ventures, Versant Ventures and Alexandria Real Estate Equities. For
additional information, please visit


Media Contact:
MacDougall Biomedical Communications
Michelle Avery or Doug MacDougall, 781-235-3060
Press spacebar to pause and continue. Press esc to stop.